Navigation Links
Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Date:2/18/2011

enrollment process is expected to begin in mid 2011 and will reach full enrollment in by end of 2012. Interim data in relation to the Phase III clinical trials is expected to be available in end of 2012 /early 2013, which will provide the first opportunity to observe statistical analysis of progression free survival. Full information on the study including key dates is available in the clinical appendix further below.

The patient population will be randomised to the CVac™ treatment arm vs. a standard of care observation arm. The objective of the trial is to further confirm the ability of CVac to reduce the instance of relapse in ovarian cancer patients, control the metastases of the cancer and increase the life expectancy of patients. Patient quality of life and patient immunological markers will also be measured.

In conjunction with the current Phase IIb trial with the US Food and Drug Administration (FDA), this trial will seek to add to the positive efficacy results from CVac's Phase IIa trial on a larger patient population. The Phase IIa trial was conducted on 28 patients in Australia and was completed in 2007.

If statistical endpoints are successfully reached in the Phase III trial, we anticipate CVac™ becoming the world's first ovarian cancer immunotherapy treatment.

Prima BioMed chief executive Martin Rogers said: "The Company is delighted that the Scientific Advice for CVac™'s Phase III Trial has been successfully received from the European regulators. With regulatory agreement for strategy and design in place, we look forward to progressing through the next important development stages. If this critical trial is successful it will provide a new paradigm for patients and oncologists globally."

Conference Call to be Hosted Tuesday, February 22nd, 2011 at 11:00 a.m. Australian EST/ Monday, February 21st, 2011 at 7:00 p.m. United States ETDr Jonathan Berek from Stanford Medical Centre, Dr Neil Frazer and J
'/>"/>

SOURCE Prima BioMed Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
8. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
9. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
10. Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM)
11. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... Berger Health System, recognized as one of the ... to AutoCarousel® HD by Talyst, a leader of pharmacy ... has a built-to-last 10 years guarantee. Berger ... is also implementing AutoPharm®, AutoPack™ and AutoLabel® to help ...
... Lineagen, Inc., an innovative molecular diagnostics company focused on ... nonprofit subsidiary of the National Multiple Sclerosis Society, today ... validation of a blood-based assay for multiple sclerosis (MS). ... test that can aid clinicians in diagnosing MS, distinguishing ...
Cached Medicine Technology:Berger Health System Partners With Pharmacy Automation Leader to Improve Patient Safety 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 3Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 4
(Date:7/11/2014)... July 11, 2014 The Europe Well Intervention ... in Europe with analysis and revenue forecast. The well intervention ... $2.4 billion in 2013 to $3.4 billion by 2018, at ... through the TOC of the Europe Well Intervention Market report, ... also provides a glimpse of the segmentation in the Europe ...
(Date:7/11/2014)... NY (PRWEB) July 11, 2014 Utilizing ... ’s own, Dr. William Koenig, has topped a record ... peers, he has performed over 400 successful procedures without ... Dr. Koenig is well known across the country for ... exceptional safety record has long been the foundation for ...
(Date:7/11/2014)... News) -- In people with sex addiction, pornography affects ... seen in drug addicts as they consume drugs, a ... brain activity between patients who have compulsive sexual behavior ... addicts," study author Dr. Valerie Voon, of the University ... release. Voon,s research involved 19 men with sex ...
(Date:7/11/2014)... 2014 (HealthDay News) -- U.S. health officials have concluded ... to live anthrax during a safety mishap last month. ... Prevention officials have announced a moratorium on the transfer ... labs. In a report issued Friday, the CDC ... sure a similar incident doesn,t occur again. Last month, ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional ... (Regular, Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, ... 2019 ” defines and segments the global probiotics ... market value of probiotic products and ingredients. The ... for the global market with an analysis of ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5
... responding to the devastation across Greece caused by this ... series of crisis map products based on satellite acquisitions ... assessment efforts following the activation of the International Charter ... people were killed and thousands left homeless in the ...
... 21 Baxa Corporation, a leading,provider of systems ... announces the addition of two new international product,distributors. ... Colombia and Pentafarma & Co. in The Dominican ... reach and expand product promotion in South,America and ...
... from DCM and Split Rock Partners, PALO ALTO, ... of its website. Caring.com will offer original "how,to" guides, ... and a community of people in caring situations, to ... million adults who are,caring for an aging relative in ...
... scientific peer review, will gather in Helsinki on 27 September ... from the fourth and final Call of the European Young ... to create teams in Europe to focus on cutting-edge science. ... from around the world to create their own research teams ...
... drugs plus insulin works best, researchers say , , FRIDAY, ... tell which insulin-plus-drug regimen might best control type 2 ... the three strategies tested coming out on top. , ... in the study can be recommended" as being superior ...
... Waltham, MA -- Brandeis neuroscientist Gina Turrigiano has been ... Award, a five-year grant totaling $2.5 million. She is ... competitive award. , According to NIH, the award ... who propose pioneering approaches to major challenges in biomedical ...
Cached Medicine News:Health News:Greeks get space-based help in wake of deadly fires 2Health News:Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic 2Health News:New Resource for Taking Care of Aging Parents Available in Beta 2Health News:New Resource for Taking Care of Aging Parents Available in Beta 3Health News:2007 EURYI: 20 researchers to receive Nobel Prize-sized awards in Helsinki 2Health News:2007 EURYI: 20 researchers to receive Nobel Prize-sized awards in Helsinki 3Health News:No Clear Winner in Diabetes Treatment Trial 2Health News:No Clear Winner in Diabetes Treatment Trial 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: